Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen

Opinion
Video

Panelists discuss how a third-line approach for a 54-year-old patient treated with a tucatinib-based regimen involves careful consideration of prior treatment responses, comorbidities, and the potential benefits of combining tucatinib with capecitabine and trastuzumab to improve outcomes in HER2+ metastatic breast cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content